Another stock that's trending within range of triggering a near-term breakout trade is
(DRTX), a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. This stock is off to a decent start for the bulls in 2013, with shares up 12%.
If you take a look at the chart for Durata Therapeutics, you'll notice that this stock has started to bounce higher today right above its 50-day moving average at $7.99 a share with above-average volume. This bounce is quickly pushing shares of DRTX within range of triggering a near-term breakout trade.
>>4 Big Stocks to Trade (or Not)
Market players should now look for long-biased trades in DRTX if it manages to break out above some near-term overhead resistance levels at $9.05 to $9.27 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 31,302 shares. If that breakout triggers soon, then DRTX will set up to re-test or possibly take out its next major overhead resistance level at its all-time high of $10.63 a share. Any move above $10.63 would then push shares of DRTX into new all-time high territory, which is bullish technical price action. Some possible upside targets off that move are $13 to $15 a share.
Traders can look to buy DRTX off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day moving average of $7.99 a share. One could also buy off strength once DRTX clears those breakout levels with volume and then simply use a stop that sits a few percentage points below your entry point.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts